Biocon Biologics Moves Quickly To Integrate Viatris In North America
Completes Integration Of Acquired Biosimilars Business ‘Ahead Of Schedule’ In US And Canada
Executive Summary
Biocon Biologics has announced the latest milestone in its integration of former partner Viatris’s biosimilars business, completing the move in the US and Canada “ahead of schedule.”
You may also be interested in...
Biocon Gets A New Group CEO As Aflibercept Approval Arrives
Biocon has named Peter Bains as its new group CEO, as the firm’s Biocon Biologics business confirmed that its aflibercept biosimilar to Eylea had become the first to receive a formal European approval.
Triple Threat: EMA Endorses Three First-Time Biosimilars
At an eventful European Medicines Agency committee meeting in July, three biosimilars from Biocon, Sandoz and Fresenius Kabi have become the first for each respective molecule – aflibercept, natalizumab and tocilizumab – to gain the endorsement of the CHMP.
Biocon Closes $3bn Deal For Viatris Biosimilars
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.